Information on these issues were discussed in sessions at the recent FTA Drug and Alcohol Conference by Jerry Powers, FTA, Drug and Alcohol Program Manager; Mark Snider, ODAPC; and Jim Keenan, FMCSA Drug and Alcohol Program Manager.
1. An electronic Chain of Custody form which will allow for an electronic signature.
2. Additional drugs added to the testing panel. The particular drugs of interest are prescription medications which include oxicodone and oxicontin (the oxies), and benzodiazepines.
When questioned, the DOT representatives confirmed that the industry can expect these actions most likely within the next 24 months.